Ftse Mib
34.339,32
0,00%
DAX
18.686,60
1,07%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,27%
Bitcoin
62.764,11
-0,45%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ TC BioPharm Holdings PLC (TCBP) TC BioPharm Holdings PLC (TCBP) Notizie

TC BioPharm Holdings PLC

TCBP
1,22
-0,02 (-1,61%)
10 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
06/5/202419:01PRNUSTC BioPharm Announces Exercise of Warrants for £3.1 Million..
06/5/202414:30PRNUSTC BioPharm Announces Execution of Second Non-Binding Letter..
04/4/202414:32PRNUSTCBP Announces Execution of Non-Binding Letter of Intent for..
02/4/202414:30PRNUSTCBP Increasing Treatment Capacity with Expanded..
19/3/202413:30PRNUSTCBP Adjourns General Meeting Until a Later Date
18/3/202413:30PRNUSTCBP Announces Exercise of Series D Warrants For Cash
06/3/202412:30EDGAR2Form 8-K - Current report
01/3/202414:30PRNUSBryan Kobel, CEO of TCBP, Appears on Nationally Syndicated..
27/2/202423:15PRNUS/C O R R E C T I O N -- TC BioPharm/
27/2/202414:30PRNUSTCBP Announces Shareholder Update Call on March 5th 2024
22/2/202415:32PRNUSTCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK..
20/2/202412:05EDGAR2Form DEF 14A - Other definitive proxy statements
15/2/202414:30PRNUSTC BioPharm Management to Participate at Upcoming 7th..
14/2/202420:48EDGAR2Form 8-K - Current report
14/2/202414:30PRNUSTCBP Provides Shareholder Update and Highlights Upcoming..
09/2/202421:26EDGAR2Form PRE 14A - Other preliminary proxy statements
29/1/202415:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
29/1/202414:30PRNUSTC BioPharm Chief Executive Officer, Bryan Kobel Featured on..
18/1/202414:30PRNUSTC BioPharm to Present at the Sequire Investor Summit
04/1/202414:46EDGAR2Form 8-K - Current report
04/1/202414:30PRNUSTC BioPharm Regains Compliance with Nasdaq Minimum Bid Price..
03/1/202414:30PRNUSTC BioPharm Announces Additional Cost Reduction Steps to..
22/12/202314:30PRNUSTC BioPharm Announces Closing of $3.5 Million Public..
21/12/202323:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/12/202314:00PRNUSTC BioPharm Announces Pricing of $3.5 Million Public..
19/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
18/12/202317:15PRNUSTC BioPharm Announces Formation of Commercial Development..
14/12/202323:20EDGAR2Form F-1/A - Registration statement for certain foreign..
13/12/202315:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202312:30PRNUSTC BioPharm Announces Plan to Implement ADS Ratio Change
27/11/202314:45PRNUSTC BioPharm Announces FDA Clearance of Phase 1B IND for..
14/11/202316:00PRNUSTC BioPharm Announces Successful Completion of Safety Cohort..
08/11/202322:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
02/11/202318:30PRNUSTC BioPharm Announces Streamlined Efficiencies and Reduces..
02/11/202318:11EDGAR2Form F-3/A - Registration statement by foreign private..
02/11/202317:57EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/10/202314:00PRNUSTC BioPharm Selects Excellos as CDMO in Anticipation of..
23/10/202314:00PRNUSTC BioPharm Announces Submission of Investigational New Drug..
29/9/202322:05EDGAR2Form F-3 - Registration statement by foreign private issuers
27/9/202314:00PRNUSTC BioPharm to Present at the LD Micro Main Event XVI
05/9/202314:30PRNUSTC BioPharm Announces Grant Funding in Collaboration with..
01/9/202323:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
31/8/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202314:30PRNUSTC BioPharm to Present at H.C. Wainwright 25th Annual Global..
28/8/202323:25EDGAR2Form F-1 - Registration statement for certain foreign..
22/8/202322:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/7/202314:30PRNUSTC BioPharm Maintains Nasdaq Listing
31/7/202314:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/7/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/7/202323:29EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
Apertura: 1,25 Min: 1,19 Max: 1,25
Chiusura: 1,24

La tua Cronologia

NASDAQ
TCBP
TC BioPharm
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network